Yahoo · Sep 10, 2026
ELTP Downgraded to Neutral on Pricing Pressure & Limited Visibility
Elite Pharmaceuticals' downgrade to Neutral cites pricing pressure, weaker revenue and margins, and limited visibility into new-product contributions.
OTC · ELTP
Healthcare · Drug Manufacturers - Specialty & Generic
$0.25
Down-$0.00 (-0.96%)
Updated Sep 19, 2026, 7:51 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ELTP does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ELTP.
ELTP research
Company profile and research snapshot.
ELITE PHARMS INC
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Elite Pharmaceuticals' downgrade to Neutral cites pricing pressure, weaker revenue and margins, and limited visibility into new-product contributions.
Yahoo · Aug 25, 2026
Elite Pharmaceuticals and Journey Medical follow different growth paths, but which looks more compelling now? Let's dive in.
Yahoo · Aug 19, 2026
ELTP's first-quarter fiscal 2027 revenues decline as generic competition and lower pricing offset higher volumes, while pipeline development remains a growth focus.
SeekingAlpha · Aug 14, 2026
Elite Pharmaceuticals, Inc. (ELTP) Q1 2027 Earnings Call August 14, 2026 11:30 AM EDTCompany ParticipantsNasrat Hakim - Chairman, CEO & PresidentCarter...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ELTP.